Cargando…

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers

Purpose: Clinical significance and durability of serological response after mRNA COVID-19 vaccines is under investigation. Data on early virological response are limited. To iden-tify potential predictors of antibody durability, circulating antibody levels were longitudinally ex-plored in healthcare...

Descripción completa

Detalles Bibliográficos
Autores principales: Cocomazzi, Giovanna, Piazzolla, Valeria, Squillante, Maria Maddalena, Antinucci, Stefano, Giambra, Vincenzo, Giuliani, Francesco, Maiorana, Alberto, Serra, Nicola, Mangia, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402545/
https://www.ncbi.nlm.nih.gov/pubmed/34452038
http://dx.doi.org/10.3390/vaccines9080913
_version_ 1783745815519428608
author Cocomazzi, Giovanna
Piazzolla, Valeria
Squillante, Maria Maddalena
Antinucci, Stefano
Giambra, Vincenzo
Giuliani, Francesco
Maiorana, Alberto
Serra, Nicola
Mangia, Alessandra
author_facet Cocomazzi, Giovanna
Piazzolla, Valeria
Squillante, Maria Maddalena
Antinucci, Stefano
Giambra, Vincenzo
Giuliani, Francesco
Maiorana, Alberto
Serra, Nicola
Mangia, Alessandra
author_sort Cocomazzi, Giovanna
collection PubMed
description Purpose: Clinical significance and durability of serological response after mRNA COVID-19 vaccines is under investigation. Data on early virological response are limited. To iden-tify potential predictors of antibody durability, circulating antibody levels were longitudinally ex-plored in healthcare workers included in a follow-up program for SARS-CoV-2 infection. Meth-ods: Subjects meeting the inclusion criteria signed an informed consent. Serum samples were col-lected at baseline, before the first BNT162b2 vaccine, at days 7, 21, 31, 90, and 180 days after the first dose. Serological evaluation was performed by QuantiVac Euroimmune anti-S1 antibody as-say. Only subjects followed-up until day 90 are here considered. Results: Of 340 taken into consid-eration, 265 subjects were naive, and 75 COVID-19 experienced. The former showed a progres-sive increase in their antibody levels before day 90 decline, while the latter showed antibody levels reaching a plateau at day 7 and slightly declining at day 90. All showed antibody levels higher than the assay cut-off at day 31 and 90. Among naive, 108 had an early response whose predic-tors were younger age and female gender (OR 0.94, 95% CI 0.91–0.96, p < 0.0001; and OR 2.58, 95% CI 1.48–4.51, p = 0.0009). Naive subjects experienced a day 30/90 decline in antibody levels, whereas experienced did not. Early response was an independent predictor of higher day 30/90 antibody levels decline (OR = 2.05, 95% CI 1.04–4.02; p = 0.037). Conclusions: Our results suggest that in healthcare workers early response might be inversely associated with antibody levels 90 days after BNT162b2 vaccine.
format Online
Article
Text
id pubmed-8402545
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84025452021-08-29 Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers Cocomazzi, Giovanna Piazzolla, Valeria Squillante, Maria Maddalena Antinucci, Stefano Giambra, Vincenzo Giuliani, Francesco Maiorana, Alberto Serra, Nicola Mangia, Alessandra Vaccines (Basel) Article Purpose: Clinical significance and durability of serological response after mRNA COVID-19 vaccines is under investigation. Data on early virological response are limited. To iden-tify potential predictors of antibody durability, circulating antibody levels were longitudinally ex-plored in healthcare workers included in a follow-up program for SARS-CoV-2 infection. Meth-ods: Subjects meeting the inclusion criteria signed an informed consent. Serum samples were col-lected at baseline, before the first BNT162b2 vaccine, at days 7, 21, 31, 90, and 180 days after the first dose. Serological evaluation was performed by QuantiVac Euroimmune anti-S1 antibody as-say. Only subjects followed-up until day 90 are here considered. Results: Of 340 taken into consid-eration, 265 subjects were naive, and 75 COVID-19 experienced. The former showed a progres-sive increase in their antibody levels before day 90 decline, while the latter showed antibody levels reaching a plateau at day 7 and slightly declining at day 90. All showed antibody levels higher than the assay cut-off at day 31 and 90. Among naive, 108 had an early response whose predic-tors were younger age and female gender (OR 0.94, 95% CI 0.91–0.96, p < 0.0001; and OR 2.58, 95% CI 1.48–4.51, p = 0.0009). Naive subjects experienced a day 30/90 decline in antibody levels, whereas experienced did not. Early response was an independent predictor of higher day 30/90 antibody levels decline (OR = 2.05, 95% CI 1.04–4.02; p = 0.037). Conclusions: Our results suggest that in healthcare workers early response might be inversely associated with antibody levels 90 days after BNT162b2 vaccine. MDPI 2021-08-16 /pmc/articles/PMC8402545/ /pubmed/34452038 http://dx.doi.org/10.3390/vaccines9080913 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cocomazzi, Giovanna
Piazzolla, Valeria
Squillante, Maria Maddalena
Antinucci, Stefano
Giambra, Vincenzo
Giuliani, Francesco
Maiorana, Alberto
Serra, Nicola
Mangia, Alessandra
Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
title Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
title_full Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
title_fullStr Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
title_full_unstemmed Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
title_short Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
title_sort early serological response to bnt162b2 mrna vaccine in healthcare workers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402545/
https://www.ncbi.nlm.nih.gov/pubmed/34452038
http://dx.doi.org/10.3390/vaccines9080913
work_keys_str_mv AT cocomazzigiovanna earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers
AT piazzollavaleria earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers
AT squillantemariamaddalena earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers
AT antinuccistefano earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers
AT giambravincenzo earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers
AT giulianifrancesco earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers
AT maioranaalberto earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers
AT serranicola earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers
AT mangiaalessandra earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers